We're thrilled to share insights from the latest episode of the Oncology Decoded podcast, where our very own Dr. Fleming joins a panel of leading genitourinary experts. The focus? Tackling one of the most pressing questions in the treatment of hormone-sensitive prostate cancer (mHSPC): When is the optimal time to enhance or intensify therapy? ?? Whether you're a healthcare professional or someone interested in the latest advancements in cancer treatment, this podcast episode is a must-listen! ??
We live in an age of rapidly advancing medical research, which means choosing the right treatment for patients can be tricky. In this episode of the Oncology Decoded podcast, panelists discussed treatment for hormone-sensitive prostate cancer (mHSPC) and the question of when--and how--to optimize or intensify therapy. The discussion included Manoj Bupathi, MD, MS, president and?medical oncologist at Rocky Mountain Cancer Centers; Benjamin Garmezy, MD, Assistant Director of Genitourinary Research at the Sarah Cannon Research Institute (SCRI); and Mark Fleming, MD, Disease Chair of the Genitourinary Cancer Research Executive Committee for SCRI at Virginia Oncology Associates. Ultimately, the conversation stressed the importance of personalized care and ongoing research, two things The Network is focused on supporting within the oncology care community. ???Listen to Episode 2 and join the conversation! https://lnkd.in/dvt-bRJW #ProstateCancer #CancerCare #CancerResearch